[ad_1]
NEW YORK (Reuters Health) – The new malaria vaccine offers long-term immunity against persistent parasites that infect hundreds of millions of people each year, a new study finds.
Most vaccines are designed to encourage the human body to respond to the pathogens responsible for the disease by creating antibodies that disrupt it. However, the new vaccine takes a different approach by using a weak form of the common herpes virus, CMV, which infects most people without causing the disease.
The new vaccine reduced the release of malaria-causing malaria parasites by the infected macaque by 75-80%, according to the results published in the January issue of One Plus.
"The problem with most vaccines is that their effectiveness is often short-lived," said lead researcher Klaus Froh, a professor at the School of Public Health at Oregon State University.
"The cytomegalovirus-based vaccine platform can create and maintain the immunity of life, and with more research and development it can provide lifetime protection against malaria."
Malaria is a serious, sometimes fatal disease caused by a parasitic infection caused by supposed parasites that spread in humans: intense fever, chills, flu-like symptoms and, in the worst case, death that can cause death. Worldwide, 216 million people became infected with malaria in 2016, resulting in the deaths of 445,000 people.
The team designed small portions of their target pathogen into cytomegalovirus (CMV), which is already used in vaccines under development to fight HIV and TB. The redesigned design produces T cells capable of searching for and destroying infected cells.
[ad_2]
Source link
